Combining protease inhibitors with new drug classes in treatment- experienced patients

Current Opinion in HIV and AIDS

Volumn 3, Issue 6, 2008, Pages 647-652

  Walmsley, Sharon ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Chemokine receptor inhibitors; HIV; Integrase inhibitors; Protease inhibitors; Treatment experienced

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLYCOPROTEIN GP 41; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VICRIVIROC; ZIDOVUDINE;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG CONTRAINDICATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LIPOATROPHY; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 67649600758     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283136c9b     Document Type: Review

References (28)

1. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society USA Panel. JAMA 2008; 230:555-570. This paper describes the latest set of guidelines for the management of ARV naive and experienced HIV infected patients.
2. European AIDS Clinical Society (EACS) Guidelines. Guidelines for the clinical management and treatment of HIV infected adults in Europe; 2007.
3. U.S Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; 29 January 2008. This paper describes the newest set of guidelines for treating the ARV-experienced patient.
4. British HIV Association (BHIVA). British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2008 (in press).
5. Hicks C, Cahn P, Cooper D, et al. Durable efficacy of tipranavir/ritonavir in combination with an optimized background of ARV for treatment-experienced HIV-1 infected patients: 48 week results of the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST) clinical trials. Lancet 2006; 368:466-475.
6. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. This article describes the pivotal trials demonstrating the role of darunavir in the management of the treatment-experienced patient.
7. Reynes J, Arasteh K, Clotet B, et al. TORO: 96 week virologic and immunological response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007; 21:533-543. This article describes the long-term follow-up for patients receiving enfuvirtide as part of salvage ARV therapy.
8. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. This paper describes the first data demonstrating the role of etravirine in the treatment-experienced patient.
9. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. This paper describes the first data demonstrating the role of etravirine in the treatment-experienced patient.
10. Trottier B, Johnson M, Katlama C, et al. Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (TMC125; ETR- in treatment-experienced HIV-infected patients [abstract no. P167]. Presented at the 17th Annual Canadian Conference on HIV/AIDS Research; 24-27 April 2008; Montreal, Quebec.
11. Vingerhoets J, Buelens A, Peeters A, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2 [abstract no.32]. Presented at the XVI International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications; 12-16 June 2007; Barbados, West Indies.
12. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures with co-administered with tipranavir boosted with ritonavir in healthy subjects [abstract 583]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado.
13. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
14. Pullen S, Sale H, Napier C, et al. Maraviroc is a slowly reversible antagonist at the human CCr5 in a CRE luciferase reporter gene assay [abstract 504]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado.
15. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872.
16. Wilkin T, Su Z, Kuritzkes D, et al. Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study for vicriviroc, a CCR5 inhibitor [abstract 655]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado.
17. Mayer H, can der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral- experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract THLB0215]. Presented at the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada.
18. Lalezari J, Mayer H, for the Motivate study team. Efficacy and safety of maraivroc (MVC) in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract H-718a]. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago, Illinois.
19. Fatkenheuer G, Konourina I, NelsonM, et al. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results [abstract P4.1/06]. Presented at the 11th European AIDS Conference; 24-27 October 2007; Madrid, Spain.
20. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract 792]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts.
21. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48-week results [abstract TUAB102]. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia.
22. Zingman B, Suleiman J, Dejesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results [abstract 39LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts.
23. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354. This article is the first description of the role of integrase inhibitors for the therapy of the treatment-experienced patient
24. Cooper D, Steigbigel R, Gatell J, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365. This article outlines the efficacy of raltegravir in various subpopulations of patients and outlines predictors of response.
25. McColl D, Fransen S, Gupta S, et al. Resistance analysis of a phase 2 study of the integrase inhibitor elvitegravir (GS-9137) [abstract no. P7.1/03]. Presented at the 11th European AIDS Conference/EACS; 24-27 October 2007; Madrid, Spain.
26. Zolopa AR, Lampiris H, Blick G, et al. The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable antiretroviral activity in treatment-experienced patients with active optimized background therapy (OBT) [Oral presentation]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, Illinois.
27. DeJesus E, Walsmley S, Cohen C, et al. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naive HIV-infected patients [abstract 929]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, Massachusetts.
28. Hazuda DJ, Miller MD, Nguyen BY, et al. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection [abstract 8]. Presented at the XVI International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications; 12-16 June 2007; Barbados, West Indies.